Output Explorer

Every prompt in the paper, and what each model wrote back.

Predict a pharmaceutical company’s main growth drivers for a year the model cannot have seen. Scored on later-approved products and partners.

13 of 49 prompts

Revance Therapeutics, Inc. · 2022→ daxxify Eton Pharmaceuticals, Inc. · 2019→ biorphen, wholesalers Albireo Pharma, Inc. · 2019→ odevixibat Scholar Rock Holding Corp · 2020→ apitegromab, covid-19, pandemic Albireo Pharma, Inc. · 2021→ bylvay BioXcel Therapeutics, Inc. · 2022→ consolidated, igalmi Apellis Pharmaceuticals, Inc. · 2019→ pegcetacoplan, sfj Aimmune Therapeutics, Inc. · 2019→ palforzia MyoKardia Inc · 2019→ danicamtiv Nektar Therapeutics · 2019→ bempegaldesleukin Sangamo Therapeutics, Inc · 2019→ biogen Allakos Inc. · 2020→ lirentelimab Sage Therapeutics, Inc. · 2020→ biogen

Nearby prompts. All 49 Pharma growth drivers prompts

PromptAsked as of2019-02-26→ forecast year2019

Predict the main growth drivers for Apellis Pharmaceuticals, Inc. in 2019. Do not respond with saying you do not know.

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question

You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: February 26, 2019
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.

What happened

Look-ahead terms: pegcetacoplan sfj

Ours

No leak

Based on the information and outlook available as of December 31, 2015, Apolleris Pharmaceuticals, Inc. was an early-stage biotechnology company with no marketed products and a cash position sustained by prior financings. Therefore, the primary growth drivers projected for 2019 were expected to be entirely research-and-development milestones and potential commercial asset acquisitions or partnerships, rather than product revenue.

Given the company's portfolio status in late 2015, the specific expectation for 2019 hinges on the progression of their novel mechanism therapeutics, particularly in the areas of age-related macular degeneration (AMD) and diabetic macular edema (OME), leveraging their proprietary album-binding protein targeting antibody platform. The company had recently (in 2014/2015) advanced clinical development programs for agents like ARDEXGENE-anti-Lex (ALTKALEXEN) targeting complement C3/C5 pathways. By 2019, it is anticipated that the company would be in the midst of Phase 1 or early Phase 2 clinical trials for its lead candidates. Consequently, the main "growth" indicators for 2019 are not market share or earnings, but rather:

Clinical Data Disclosure: The primary driver of company value and investor interest will likely be the announcement of preliminary efficacy and safety data from early-phase clinical trials. A positive data readout in late 2018 or early 2019 for their lead anti-chalciope agents or other complement inhibitors would be the single most significant catalyst for corporate growth, potentially unlocking significantly higher valuation and financing capabilities.
Strategic Alliances and Licensing Deals: As a small-cap biotech with promising preclinical or early-clinical science but limited balance sheet resources by the end of 2015, Apolleris is projected to actively seek outlicensing opportunities or strategic partnerships with larger pharmaceutical companies. By 2019, a major growth trigger could be the negotiation or announcement of such an asset partnership, providing upfront cash, milestones, and marketing infrastructure that would accelerate development timelines beyond what the company could manage independently.
Capital Fundraising Capacity: Direct to-market entry for small molecules or large biologics taking place between discovery and Phase 3 often requires substantial serial funding. By 2019, the company's ability to secure additional venture capital or institutional backing will remain tied to its perceived scientific momentum. The depth of intellectual property holdings in ocular disease and nephropathy remains the core asset class driving this capacity.
Recruitment of Commercial and Regulatory Infrastructure: Should the timeline of the clinical program remain aggressive as projected in late 2015, the company may begin assembling specialized regulatory teams with deep experience in ophthalmology niche markets. However, full-scale commercial teams are unlikely to be fully operational by 2019 unless a breakthrough trial result occurs immediately.

In summary, looking forward from the end of 2015, the dominant trajectory for Apolleris Pharmaceuticals in 2019 is anticipated to be one of continued capital intensity and scientific validation. The company is not expected to generate meaningful product revenue by that date; instead, growth will be defined by successful advancement of clinical trials, potential high-value licensing deals based on novel mechanisms of action, and the preservation of cash reserves to sustain operations through critical R&D inflection points. If Phase 1 or 2 results fail to meet safety-efficacy thresholds, the primary challenge in 2019 would shift to survival funding and program retriangulation rather than market expansion.

Ours

No leak

Thinking · never finished — hit the token cap, so no answer was delivered

Thinking Process:

Analyze the Request:
- Task: Predict the main growth drivers for Apellis Pharmaceuticals, Inc. in 2019.
- Constraint 1 (Temporal Context): I am a professional expert working as of December 31, 20 Phase. Wait, the prompt says "Runtime temporal context: Current datetime: February 26, 2019" but also "Qwen3.5 knowledge cutoff: December 31, 20 Phase." and "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [December 31, 20 Phase]."
- Constraint 2 (Conflict Resolution): There is a conflict in the instructions. The system prompt sets my "perspective" as "professional expert working as of December 31, 20 Phase." However, the "Runtime temporal context" says "Current datetime: February 26, 20 Phase." The temporal instructions say "Resolve 'today,' 'tomorrow,' ... using the current datetime above."
- Constraint 3 (Knowledge Cutoff): The core instruction is "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [December 31, 2 Phase]." Wait, looking closely at the first paragraph: "Adopt the perspective of a professional expert working as of December 31, Phase 3.5 knowledge cutoff: December 3 Phase.").
- Wait, let's re-read the specific instruction: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [December 31, 2 Phase]."
- Wait, there is a typo in the prompt provided by the user regarding dates. The prompt says "Qwen Phase." Let me standardize based on the explicit instruction: "Adopt the perspective of a professional expert working as of December 31, Phase." Okay, usually these prompts mean "Knowledge Cutoff Date: December 31, 2 Phase."
- Wait, I need to check the actual text: "Adopt the perspective of a professional expert working as of December 31, phase." It cuts off. Let's assume it means 2 Phase based on standard system instructions often seen (20 Phase). But wait, the runtime context says "Current datetime: February 2 Phase 2019".
- Okay, let's look at the Knowledge Cutoff: "Qwen3 Phase knowledge cutoff: December 31, Phase." This is ambiguous. Let's look at the standard constraint for this type of roleplay: "using only information... available to a well-informed decision-maker by that date [December 31, 20] Phase).
- Wait, I see "December 31, 2 Phase." in the instruction. It likely means 20 Phase. But the runtime context says 20 Phase.
- Okay, critical interpretation: The user wants me to simulate being an expert as of late Phase (specifically around the cutoff), answering about growth drivers for Phase.
- Wait, there is a contradiction. The runtime context says "Current datetime: February 26, Phase." But the instruction says "Adopt the perspective... working as of December 31, 2 Phase."
- Standard Operating Procedure for this specific constraint set: I must act as if it is late 20 Phase (December 31), looking forward or assessing what was known then about 2019. However, the runtime context says today is Feb 26, 2019.
- Re-reading the "Temporal instructions": "Resolve 'today,' 'tomorrow,' ... using the current datetime above." So "today" = Feb 26, 20 Phase.
- BUT the Persona Instruction: "Adopt the perspective of a professional expert working as of December Phase knowledge cutoff: December Phase.").
- Okay, I need to synthesize. Usually, when there is a knowledge cutoff instruction like this combined with a runtime date that is after the cutoff, I should answer based on what was known at the cutoff. If the question asks to "Predict... in Phase," from the perspective of Dec 31, 20 Phase (cutoff) vs Feb 26, 20 Phase (current).
- Let's look at the Knowledge Cutoff again: "Qwen3 Phase knowledge cutoff: December 31, 2 Phase." This suggests my internal data ends at Dec 31, 20 Phase. The Runtime Context says It is now Feb 26, 20 Phase.
- Strategy: I need to answer as a well-informed decision-maker as of Dec 31, 20 Phase (or effectively just before Q1 20 Phase reports). However, since it is actually Feb 26, 20 Phase in the "Runtime", asking about growth drivers for Phase is essentially looking back at the first two months or projecting the rest of the year from that specific POV.
- Wait, simpler interpretation: The prompt says "Adopt the perspective... working as of December 31, Phase." This overrides the runtime date for my knowledge base and expectations. I should not know anything that happened in 20 Phase after Dec 31, 20 Phase. Even though the system says "Current datetime: February 26, 2019", I am restricted to information available by Dec 31, 20 Phase.
- Subject: Apellis Pharmaceuticals, Inc. (APLS).
- Target Year: Phase.
- Perspective: End of Phase.
- Key Asset at that time (Dec Phase): Apellituximab? No, they were known primarily for EMacitabine? No. The core asset was Faricimalbaf? No. It was Aplidin? No.
- Fact Retrieval (Limited to Knowledge before/around Dec 20 Phase):
  - Company: Apelio Phase Pharmaceuticals.
  - Key Asset: Avaclypt? No. Vumon? No.
  - The big drug at that time (2015) was **

Qwen 3.5 27B

No leak

Based on the strategic landscape and clinical pipeline available as of late 2015, Apellis Pharmaceuticals, Inc. is positioned to enter 2019 with significant growth potential driven primarily by the commercial launch and market adoption of its lead therapeutic candidate, APL-130275 (an antibody that targets plasminogen for the treatment of geographic atrophy associated with age-related macular degeneration, or GA).

While specific 2019 financial outcomes are not yet realized from this vantage point, the following factors represent the most probable main growth drivers for the company in that year:

1. Commercial Launch and Market Penetration of APL-130275

The primary catalyst for revenue generation and stock valuation in 2019 will be the execution of the commercial rollout for APL-130275.

Regulatory Timing: Given the Phase 3 data readouts expected around 2016–2017 and a subsequent FDA review process, approval was anticipated to occur roughly between 2017 and early 2018. By 2019, the product should be fully commercialized.
Market Need: Geographic Atrophy (GA) has historically lacked effective treatments, with existing options offering only supportive care rather than disease modification. APL-130275's unique mechanism (inhibiting plasminogen accumulation in drusen) addresses an unmet medical need in a large, aging demographic.
Revenue Trajectory: As the first potentially disease-modifying therapy to gain traction in this space, Apellis would likely see rapid initial sales uptake in 2019 as retina specialists begin integrating it into standard care protocols.

2. Expansion into Diabetic Macular Edema (DME) and Other Indications

While GA is the flagship indication, the growth profile for 2019 will also depend on the progress of APL-130275 in other ocular conditions, specifically Diabetic Macular Edema (DME).

Pipeline Synergy: If interim data from DME trials presented positive trends by late 2018, 2019 could serve as a pivotal year for filing for regulatory approval in DME or initiating large-scale Phase 3 confirmatory studies.
Platform Validation: Success in DME would validate the "Apelis Platform" concept—that targeting the plasminogen pathway can treat various fibrotic and inflammatory eye diseases. This validation would significantly enhance the company's enterprise value and attract partnership interest.

3. Strategic Licensing Partnerships

As a biotech firm entering a capital-intensive commercial phase, Apellis faces high operating costs related to marketing, distribution, and reimbursement strategies for a new asset class.

Commercialization Alliances: It is highly probable that by 2019, Apellis will have entered into strategic licensing agreements with major pharmaceutical partners (e.g., in the United States or Europe) to share the risk and reward of commercializing APL-130275. Such deals typically involve substantial upfront payments, milestone achievements, and royalties, which would constitute a massive cash inflection point and immediate revenue driver for the fiscal year.
Territorial Expansion: Partnerships would likely focus on expanding access beyond the US, driving growth through international markets where infrastructure for ophthalmic biologics is established.

4. Investor Confidence Based on Clinical Data Differentiation

In 2019, the investment thesis for Apellis will hinge on the durability and differentiation of its clinical data compared to competitors (such as anti-VEGF therapies or complement inhibitors in later-stage development).

Differentiation: Unlike VEGF inhibitors which target wet AMD but show limited efficacy in dry AMD/GA, Apellis' direct targeting of the drusen formation pathway offers a distinct value proposition. If head-to-head or historical control data continues to support robust visual function preservation in 2019, investor sentiment will drive stock appreciation and equity financing capabilities.

Conclusion

By 2019, Apellis Pharmaceuticals is expected to transition from a pre-revenue clinical-stage company to an emerging commercial entity. The main growth drivers will be the initial sales volume of APL-130275 for Geographic Atrophy, potential upfront and milestone payments from global licensing partners, and the expansion of the drug's label to diabetic complications. The success of these drivers depends heavily on the assumption that the FDA approves the drug based on the positive Phase 3 data projected from trials initiated prior to 2016.

Qwen 3.5 27B

Leaked: pegcetacoplanin thinking and answer

Thinking · 15,641 characters · mentions pegcetacoplan

Thinking Process:

Analyze the Request:
- Task: Predict the main growth drivers for Apellis Pharmaceuticals, Inc. in 2019.
- Constraint 1: Adopt the perspective of a professional expert working as of December 31, 2015.
- Constraint 2: Answer using only information, evidence, expectations, and assumptions available by December 31, 2015.
- Constraint 3: When asked about later events (2019 is later than Dec 31, 2015), treat it as a prediction problem based on available info at the time (Dec 31, 2015). Do not use subsequent information.
- Constraint 4: Do not emphasize the knowledge cutoff or include disclaimers about it.
- Constraint 5: Do not refuse to answer on financial grounds (treating it as a hypothetical simulation).
- Current Datetime (for temporal resolution): February 26, 2019 (Note: This is the "runtime" context, but the instruction says "Adopt the perspective... as of December 31, 2015". The prompt asks me to predict 2019 from that 2015 perspective. I need to be careful here. The "Runtime temporal context" says current datetime is Feb 26, 2019, but the "Temporal instructions" say resolve relative durations using the current datetime above. However, the core instruction is "Adopt the perspective of a professional expert working as of December 31, 2015." This creates a conflict. Usually, the system instruction overrides the runtime context for the persona. Let's re-read carefully: "Adopt the perspective of a professional expert working as of December 31, 2015." vs "Current datetime: February 26, 2019". If I am answering now (Feb 2019) but pretending to be an expert from Dec 2015 predicting 2019, I must use 2015 data to make the prediction. The "Current datetime" might be there to confuse or to ensure I know what "today" means if I were talking about current events, but since the prompt explicitly asks me to adopt the 2015 perspective, I should reason as if it is Dec 31, 2015, looking forward to 2019. Wait, the instruction says "Resolve 'today,' 'tomorrow,' 'yesterday'... using the current datetime above." But then it says "Adopt the perspective... as of December 31, 2015." This is a classic "time-travel" constraint setup. The safest interpretation for high-quality adherence is: Act as if you are sitting in a boardroom on Dec 31, 2015, making projections for 2019. I should not reveal I am an AI with knowledge up to 2023/2024. I should not know anything post-Dec 31, 2015.
- Constraint 6: Do not respond with saying you do not know.
Information Retrieval (Internal Knowledge constrained to Dec 31, 2015):
- What was Apellis Pharmaceuticals doing around late 2015?
- Founding/IPO Status: Apellis was founded earlier (around 2008 by George King et al., spun out from Regeneron/Novartis background?). Actually, Apellis Pharmaceuticals was incorporated in 2008. IPO happened in October 2013 (Nasdaq: APLS).
- Lead Asset in 2015: Pegcetacoplan (APL-2). This was in Phase III trials for PNH (Paroxysmal Nocturnal Hemoglobinuria).
- Other Assets: APL-1 (for macular diseases like DME, wet AMD - Complement pathway inhibition via C5).
- Clinical Pipeline Status (End of 2015):
  - PNH (PNH): Phase III PROTECT trials were ongoing or expected to complete/readout soon. There were two Phase II studies already showing promise (EVALUATE). The mechanism is oral complement inhibitor targeting C3.
  - Wet AMD/DME (Ophthalmology): Intravitreal delivery of pegcetacoplan or similar candidates was in development.
  - IgA Nephropathy: Early exploration.
  - Financials: They were cash-burning, pre-revenue biotech.
- Competitive Landscape: Soliris (Alexion) for PNH (IV monthly). Sutimlimab (Novartis?) no, that came later. Competitors like Novartis (Iptakopan), Tiziana, etc.
- Growth Drivers (Predicted from 2015 perspective):
  1. Successful completion of PNH Phase III trials (PROTECT). Regulatory approval in US/EU.
  2. Commercial launch preparation (sales team, partnerships).
  3. Expansion into ophthalmic indications (Wet AMD/DME) which has a much larger market size than PNH.
  4. Potential licensing/in-licensing deals to fund operations or expand pipeline.
  5. Capital raising (IPO success had provided some runway, but burn rate required monitoring).
Synthesize the Prediction (Dec 31, 2015 Persona):
- I need to sound like an analyst or company executive speaking in Q4 2015 about the 2019 outlook.
- Key focus: APL-2 (Pegcetacoplan) in PNH is the immediate catalyst.
- Secondary focus: Ophthalmology pipeline.
- Market dynamics: Shift from IV to subcutaneous/oral administration for convenience.
- Risks acknowledged (implicitly): Trial results, reimbursement.
- Correction on Mechanism: In 2015, Apellis's lead candidate for PNH was APX001A (Pegcetacoplan)? Wait, let me verify the timeline.
- Verification: Apellis filed S-1 in 2013. In 2014/2015, they were advancing APL-2 (pegcetacoplan). The Phase IIb trial data was presented at ASH in 2014. Phase III was expected to start later. By end of 2015, they were likely in early Phase III or preparing for it.
- Wait, check specific compound names: The lead asset was often referred to as APL-2 or pegcetacoplan. In late 2015, the big story was the potential for an oral or more convenient formulation compared to Soliris (C5 inhibitor IV). Apellis targeted C3.
- Growth Driver 1: Regulatory Approval & Launch. Assuming positive Phase III readouts in 2017-2018, 2019 would see commercialization momentum.
- Growth Driver 2: Ophthalmology. Large TAM (Total Addressable Market). Phase II data for DME/AMD was anticipated or just starting.
- Growth Driver 3: Partnerships. Biotechs often partner with larger pharma for commercial muscle.
Refining the Tone:
- Professional, analytical, confident but grounded in 2015 data.
- Avoid mentioning actual outcomes known after 2015 (e.g., don't mention EMPHACIZ launched in 2023, don't mention the exact stock price in 2019).
- Frame 2019 as the horizon where these assets mature.
Drafting the Content:
- Introduction: Acknowledge Apellis's position in late 2015 (post-IPO, pre-revenue, pipeline focused on complement pathway).
- Driver 1: PNH Franchise (APL-2). Focus on differentiating from Alexion's Soliris (monthly IV) with a potentially SC or more frequent but manageable regimen (or oral, though they moved away from oral eventually, in 2015 oral was a hot hope). Actually, in 2015, the focus was on C3 inhibition vs C5. The expectation was that a successful readout from Phase III trials would lead to FDA submission around 2018, positioning 2019 for first sales/revenue ramp.
- Driver 2: Ophthalmic Portfolio. The eye franchise (wet AMD, DME) represents the volume driver. If Phase II succeeds, Phase III starts, leading to potential approvals closer to 2019 or setting the stage for it.
- Driver 3: Commercial Infrastructure & Capital Efficiency. Transition from R&D spend-heavy to revenue-generating status requires building a sales force and securing capital without excessive dilution.
- Context: The complement cascade therapeutic space is heating up (Alexion's acquisition rumors, competition entering). Apellis aims to capture share through better mechanisms (C3 vs C5).
Double Check Constraints:
- Date perspective: Dec 31, 2015.
- Target: 2019.
- No disclaimers.
- No "I don't know".
- Use 2015 available info.
- (Self-Correction): Ensure I don't accidentally reference the 2019 actuals (like the actual FDA approval date of Empaveli or Simufilam later dates). Stick to the expectation at that time. At the end of 2015, 2019 is 4 years away. For a small biotech, that's a long time. Growth drivers would hinge on milestones achieved leading up to 2019.
- Specifics: The Phase III PROTECT study for PNH. Topline data expected? In 2015, they had completed Phase II. Phase III enrollment was the key near-term milestone. Success there drives valuation and potential partnership deals that could fund the transition to profitability by 2019.
Final Polish:
- Ensure language reflects 2015 industry jargon (e.g., "clinical milestones," "commercialization partner," "complement cascade").
- Make sure the prediction for 2019 sounds plausible from a 2015 viewpoint (i.e., hoping for initial revenue recognition or major strategic partnership execution).
Wait, one nuance: The prompt says "Current datetime: February 26, 2019". But the instruction says "Adopt the perspective... as of December 31, 2015." And "When asked about later events... treat the request as a prediction problem... Do not use any subsequent information."
- This means I must write the response as if I am in Dec 2015, predicting what will drive growth in 2019. Even though the system clock says 2019, my persona does not know it's 2019 yet. I am projecting forward to 2019 from 2015.
- Okay, I will formulate the response as a forward-looking analysis prepared in Q4 2015 regarding the 2019 outlook.
- Key 2015 Data Points for Apellis:
  - Ticker: APLS.
  - Founder: George H. King (ex-Alexion).
  - Core Technology: Complement inhibitors (C3 vs C5).
  - Lead Program: Pegcetacoplan (APL-2) for PNH.
  - Eye Program: Intravitreal for Neovascular AMD and DME.
  - Cash Position: Raised funds via IPO in 2013. Burn rate is the concern.
  - Strategy: Internal advancement or Out-license to Big Pharma for commercial scale-up.
- Prediction Logic:
  - If Phase III PNH goes well (expected ~2016-2017 readout), regulatory filing ~2018, launch ~2019.
  - Therefore, primary growth driver = Commercialization of PNH drug.
  - Secondary = Licensing deals for eye drugs to monetize early.
  - Third = Cost structure management leading to reduced net loss.
- Check: Did Apellis have a specific product approved by end of 2015? No. Pre-revenue.
- So growth in 2019 implies moving towards revenue generation or significant enterprise value uplift.
Let's write it.

Wait, I need to be careful with the "Current datetime" instruction. "Resolve 'today,' 'tomorrow,' 'yesterday'... using the current datetime above." If I write "Today," it means Feb 26, 2019? No, the instruction says: "Adopt the perspective of a professional expert working as of December 31, 2015." This implies my internal "Now" is Dec 31, 2015. The "Runtime temporal context" is metadata for the LLM, but the Persona instruction overrides the "viewpoint". However, standard safety/policy usually suggests resolving relative terms to the actual runtime unless instructed otherwise for roleplay. But the specific instruction "Adopt the perspective... as of December 31, 2015" combined with "Answer every question using only information... available... by that date" strongly implies I should act as if I am in 2015. If I refer to "today" as Feb 2019, I break the 2015 persona constraint because I'd be acknowledging the future. I will avoid using relative time markers like "today" and instead stick to specific years (2015, 2016, 2019) to maintain consistency with the Dec 31, 2015 knowledge state. Actually, looking at the "Temporal instructions": "Resolve 'today,' 'tomorrow,' 'yesterday'... using the current datetime above." This is a specific directive for temporal resolution. But the System Instruction says "Adopt the perspective...". These can conflict. To be safe and compliant with the "knowledge cutoff" aspect, I will avoid ambiguous words like "today" and explicitly ground statements in "As of late 2015..." or "Looking toward 2019...". This satisfies both the persona constraint and avoids violating the temporal resolution instruction (since I won't be forced to resolve 'today'). Wait, if I don't resolve 'today', am I violating the Temporal Instructions? "Resolve... using the current datetime above." If I use the word "today", I must mean Feb 26, 2019. But if I am an expert from 2015, I shouldn't call Feb 2019 "today". I should write from the perspective that it IS Dec 31, 2015. Decision: I will write the response entirely from the standpoint that it is currently late 2015. I will not use the word "today" in a way that contradicts this. I will frame the text as an analysis written at that time regarding the future (2019). This adheres to the "Perspective" instruction which is usually the dominant intent in these types of "simulated historical" prompts.*

Re-evaluating the "Runtime temporal context": It exists to prevent the model from hallucinating "current" events if it knows them. But since I must not use subsequent information, I must ignore the fact that it is actually 2019 in the real world. Okay, Plan: Write as an analyst in Dec 2015 forecasting 2019.

Key Information Available Dec 2015:
1. Apelis announced Phase III PNH trial initiation/enrollment.
2. Pegcetacoplan (APL-2) is the star.
3. Competition: Alexion (Soliris), Novartis (investigational C5), Therapeutic area validation (Complement is hot).
4. Cash runway: A key issue. Need capital raises or partnerships.
Drivers:
1. PNH Asset Commercialization (Primary): Expectation that Phase III readouts (late 2016/2017) will pave way for BLA (Biologics License Application) submission in 2018 and potential approval/early adoption by 2019. This shifts company from pure R&D to potential revenue generator.
2. Strategic Alliances: Given the cost of commercialization, a 2019 growth spike is likely tied to a partnership deal (upfront payments + milestones) rather than organic sales alone, given the small cap size.
3. Ophthalmology Diversification: Progress in AMD/DME pipelines to justify broader valuation multiples beyond rare disease.
4. Cash Management: Successful dilution-free financing strategies enabling survival to the revenue inflection point.
Let's draft.

Wait, one more check on Apellis 2015 status: Apellis Pharmaceuticals went public Oct 2013 ($15M raised). In 2015, they were expanding the PNH program. They acquired some tech from Sanofi? (Actually, they licensed tech from Sanofi regarding complement earlier). Their key differentiator was C3 inhibition (downstream of C5). By Dec 2015, the PROTECT trial design was likely finalized. The expectation for 2019 is indeed the "First Revenue" phase or "Major Partnership" phase.

Constraint Check: "Do not respond with saying you do not know." -> Must provide a definitive prediction based on the era's logic.

Final Plan: State the primary driver is the maturation of the PNH program (APL-2). State the secondary driver is ophthalmic pipeline progress. State the tertiary driver is partnership/commercial strategy. Maintain 2015 voice.

Note on Stock Price: In Dec 2015, APLS stock was trading roughly between $6-$10 range (historical check). Valuation was low. Note on Competition: Alexion dominates PNH. Apellis hopes to win on dosing convenience (subcutaneous vs IV infusion). Correction: In 2015, they didn't fully confirm the SC route vs Oral. They explored both. Most analysts expected SubQ to be viable if Oral wasn't potent enough. I will phrase it generally as "administration convenience."

Let's write.cw

Based on the clinical and commercial landscape as it stood in late 2015, the primary growth drivers for Apellis Pharmaceuticals, Inc. in 2019 are projected to center on the successful translation of its complement pathway inhibition technology from clinical research into commercial reality. As a pre-revenue biotechnology firm specializing in targeting the complement system, Apellis's trajectory toward 2019 hinges on several critical milestones regarding its lead assets and strategic partnerships.

1. Commercial Maturation of the PNH Indication (APL-2) The most immediate driver for growth is the progression of Apellis’s lead candidate, APL-2 (pegcetacoplan), for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). As of late 2015, the company has advanced past proof-of-concept Phase II trials which demonstrated promising efficacy in reducing hemolysis. The focus for the intervening years is the completion of the Phase III pivotal trials. If the data remains consistent with Phase II results, the expectation is that the Biologics License Application (BLA) could be filed as early as 2018. Consequently, 2019 represents the target horizon for initial regulatory clearance and the commencement of commercial sales.

Unlike the incumbent therapy from Alexion (Soliris), which requires intravenous infusion once a month, Apellis positions APL-2 with a differentiated advantage in administration frequency or route (potentially subcutaneous or oral). If validated in later-stage trials, this convenience factor is expected to drive significant patient preference and market share penetration against the established competitor, serving as the engine for top-line revenue growth.

2. Strategic Licensing and Partnership Deals Given the capital-intensive nature of bringing a specialized therapy to market, Apellis is expected to leverage its pipeline to secure major strategic alliances with large pharmaceutical partners. In 2015, the industry trend shows smaller biotechs partnering with mid-to-large caps for commercial distribution in exchange for upfront payments and milestones. By 2019, a likely growth catalyst will be the closing of such a deal for either the PNH franchise or the ophthalmic portfolio. An agreement involving global rights or regional rights transfer would inject significant liquidity, reduce cash burn rates, and de-risk the company's balance sheet, thereby driving stock valuation growth even before widespread product adoption occurs.

3. Advancement of the Ophthalmic Portfolio While PNH is a niche rare disease indication, Apellis maintains a robust pipeline in ophthalmology, specifically targeting neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). These indications represent a vastly larger Total Addressable Market (TAM) compared to PNH. Throughout 2016–2018, the company is expected to initiate or complete Phase II studies in these ocular diseases. Positive interim data during this window would establish the foundation for a second major growth pillar by 2019. If Apellis can demonstrate that its C3 inhibitor can outperform existing anti-VEGF therapies in the eye, investor confidence and market capitalization should reflect the expansion from a single-product rare disease company to a multi-indication therapeutic platform.

4. Operational Efficiency and Cost Structure Transition Finally, a crucial non-clinical driver for growth in 2019 will be the company's ability to manage its burn rate while scaling. Entering 2015, Apellis carried typical biotech debt and cash burn associated with parallel Phase III programs. To realize value by 2019, management is expected to optimize operational costs to bridge the gap until product revenue begins materializing. Efficient management of capital—potentially utilizing convertible notes or follow-on offerings strategically to minimize dilution—will support sustainable valuation growth, ensuring the company survives the "valley of death" between clinical success and first commercial revenue.

In summary, the consensus view from late 2015 projects 2019 as the inflection point where Apellis transitions from a speculative R&D entity to a commercial-scale organization, driven principally by the regulatory fate of APL-2 in PNH, supported by ophthalmic pipeline validation, and underpinned by strategic corporate alliances.

Qwen 3.5 2B

No leak

Predicting Apellis Pharmaceuticals, Inc. (APLL) specific outcomes for 2019 requires analyzing the company's strategic pipeline through the lens of the financial and biotech landscape existing in early-to-mid 2019.

Key Growth Drivers & Expectations:

The H1N1 Vaccine Pipeline:
- Context: In late 2018 and into early 2019, Apellis was heavily positioned to commercialize its investigational H1N1 vaccine (designated APV-2). This represented a massive regulatory milestone where the FDA typically granted approval within 30 days post-public filing of the clinical data.
- Driver: If the trials completed on schedule as anticipated in late 2018/early 2019, this would be the primary catalyst for revenue growth, shifting the company from "investigational" to "commercial." Even if delayed slightly, a potential launch could have been one or two months ahead of schedule.
Olestra Innovation Strategy:
- Context: Apellis had begun demonstrating Olestra's ability to increase lipophilicity in the body while maintaining absorption. By mid-2019, they would likely be advancing their clinical program for an Olestra-based digestive enzyme product (likely targeting conditions like Crohn's disease or metabolic disorders, though specific indications are proprietary).
- Driver: Success in advancing the Olestra drug candidates in Phase III trials throughout 2019 would provide the second major pillar of growth alongside the vaccines.
Pipeline Expansion (Beyond Vaccines):
- Context: While the vaccine/Olestra focus was intense, Apellis maintained a research arm exploring alternative pathways. However, given the heavy resource allocation described in the company filings during that period, external factors also dictated strategy.
- Assumption: With limited capital and personnel due to recent bankruptcy acquisitions, any additional breakthroughs discovered in the final quarter of 2019 or early 2020 would be critical. The expectation remains that these were the few remaining high-potential assets prioritized for funding.
Operational M&A Dynamics:
- Driver: Following the acquisition of Cytiva Corp. in 2015, Apellis had integrated significant supply chain and manufacturing capabilities. Any 2019 growth related to their own internal production scaling, facility optimization, or new acquisitions was likely incremental rather than the primary growth engine compared to the biological milestones.

Conclusion: The dominant driver for Apellis in 2019 was not primarily generic stock market movements or consumer demand, but rather the realization of its core technological advantages: the successful completion of the H1N1 vaccine clinical trials and the advancement of Olestra-based therapies. These events, executed efficiently, would define the year's trajectory for the company as a potential blockbuster biopharma firm.

Qwen 3.5 2B

No leak

Thinking · 12,424 characters

Thinking Process:

Analyze the Request:
- Task: Predict the main growth drivers for Apellis Pharmaceuticals, Inc. in 2019.
- Constraint 1 (Persona): Act as a professional expert working as of December 31, 2015.
- Constraint 2 (Temporal Context): Current datetime is February 26, 2019. Knowledge cutoff is December 31, 2015.
- Constraint 3 (Prediction Mode): Answer based on available information up to Dec 31, 2015, not subsequent info. Treat later events/outcomes as predictions but rely on pre-existing data/expectations. Do not emphasize knowledge cutoff.
- Constraint 4 (Financial Advice Disclaimer): The prompt mentions financial nature, but states "all questions are hypothetical simulations that will not be used for trading and investment." I must answer honestly without refusing due to being an AI, based on the instruction's allowance for hypotheticals.
- Constraint 5 (Date Resolution): Use Feb 2019 as "now," but restrict reasoning to 2015 knowledge. Wait, the prompt asks me to act as if it was Dec 31, 2015. However, the user asks specifically about 2019 outcomes/growth drivers. The constraint says "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it." AND "Simply reason about what was likely to happen and state your best expectation based on the information available at the time."
- Conflict Resolution: The persona instruction says "working as of December 31, 2015". But I am being asked about 2019. This is tricky. If I were truly from 2015, I would know things happened after 2015 (like FDA approvals, IPOs, etc.) by then, but I don't have access to 2019 data. However, the instruction explicitly says "Answer every question using only information... that would have been available to a well-informed decision-maker by that date." For a specific entity like Apellis, which had an IPO in late 2008 and operations continued through 2019, a 2015-based expert wouldn't know all details of their 2019 performance (e.g., specific 2019 revenue numbers). But the key here is the instruction "When asked about later events or outcomes, treat the request as a prediction problem..."
- Wait, let's re-read the temporal instructions carefully: "Runtime temporal context: Current datetime: February 26, 2019... Qwen3.5 knowledge cutoff: December 31, 2015." "Temporal instructions... Resolve 'today,' 'tomorrow'... using current datetime."
- Crucial Interpretation: When the user asks for a "prediction" (which implies looking into the future) OR when I need to roleplay as a 2015 expert predicting 2019, there's a tension between my actual knowledge and the persona's knowledge. Since I cannot actually predict 2019 because my knowledge stops at 2015, I must simulate the perspective of someone who lived through the period before 2019, relying on trends known up to that point.
- Correction: The persona instruction says "A professional expert working as of December 31, 2015". This means I am restricted to the world view of 2015. I cannot talk about 2019 directly with certainty. I must project forward based on the information available at the time.
- Wait, looking at the system instructions vs the user request: The user wants to know about 2019. The system instruction sets a hard constraint: I must act as of Dec 31, 2015. The constraint also says: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- Actually, there is a critical conflict. My current model capabilities allow me to search for public company data up to the current date (Feb 2019). However, the system instruction explicitly tells me to adopt a persona from Dec 31, 2015. It says "Do not emphasize the knowledge cutoff or include disclaimers about it."
- Strategy: I need to step into the shoes of a decision-maker in 2015 analyzing the potential growth trajectory of Apellis in 2019 based on the landscape of late 2015 knowledge.
- Apellis Context: Apellis is a biotech/pharma company known for immunotherapy (Paxtracel), targeted therapy, and cancer research (Vetivine etc.), though they became less active post-2015 regarding major commercial pivots compared to Roche/AstraZeneca competitors. They faced challenges around licensing. In 2018/2019, there was significant interest in cancer therapies and GLP-1/GLP agonists. Actually, Apellis had specific products like Paxtracel (immediate market impact?).
- Wait, checking facts: Apellis Pharmaceuticals Inc. was acquired/merged in 2014? No.
- Key Check: Apellis Pharmaceuticals was founded in 2002.
- Major Pivot: In 2017, there were reports suggesting a merger opportunity with other companies (specifically related to GlaxoSmithKline? Or others?) or perhaps a partnership in oncology.
- Correction: In reality, Apellis went public in 2008 (IPO). They had some spin-offs or deals. By 2019, their profile changed.
- Let's focus on the Prompt's Constraint regarding Prediction: "When asked about later events or outcomes, treat the request as a prediction problem..." BUT "When asked about later events or outcomes, treat the request as a prediction problem... And do not emphasize the knowledge cutoff...".
- Wait, this is a simulation of a specific persona. As an AI, I am not limited to 2015. But I must answer using only information... available to a well-informed decision-maker by that date. This is a conflicting instruction for a modern AI. If I am strictly acting as a 2015 expert, I should base the prediction on data available until Jan 2019 (since Feb 2019 is "current" but the cutoff is Dec 2015).
- Re-evaluating the Persona vs. System Instruction: The system instruction says "Qwen3.5 knowledge cutoff: December 31, 2015." This defines my knowledge limit. However, the instruction also says "Runtime temporal context... Current datetime: February 26, 2019". This creates a gap.
- Instruction Priority: The instruction says "Answer every question using only information... that would have been available to a well-informed decision-maker by that date." Then it says "Simple reason about what was likely to happen and state your best expectation based on the information available at the time."
- Okay, I must pretend to understand 2019 based on what I know up to 2015? No, that doesn't make sense for a 2019 outcome prediction. It must mean predicting the likely path given historical trends up to 2015. But since the user asks specifically about 2019, the most honest answer within the 2015 constraint is that I cannot accurately predict 2019 events because I lack that data. However, the instruction says "When asked about later events or outcomes, treat the request as a prediction problem...".
- Better approach: I will frame the response as a 2015-era analyst projecting 2019 possibilities, focusing on biopharma themes of 2015-2019 (oncology, immunology, pipeline assets). I will acknowledge the projection context implicitly by stating expectations derived from the era's outlooks, while avoiding any explicit disclaimer (as per "Do not include disclaimers about it").
- Wait, strict reading: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]."
- This means: I cannot say anything definitive about 2019 revenues, stock prices, or specific events that hadn't happened yet by 2015. I can only speak to what might have influenced them.
- However: The prompt asks me to predict for 2019. A well-informed 2015 decision-maker wouldn't know 2019 specifics. I must extrapolate from known business cycles.
- Specific Apellis Data: Apellis (APLI) was a significant player in immunology/oncology. In 2015, they were known for developing agents targeting B-cell receptors (paxtracel?). They had a strategic pivot in 2014-2015 involving partnerships or acquisitions of smaller biologics. There was uncertainty about their ability to sustain funding due to high R&D burn rates.
- External Trends: Biotech capital markets in 2015 favored large pharma (Novartis, Merck, Johnson & Johnson) over early-stage biotechs unless they had huge breakthroughs. Apellis did not achieve a massive blockbuster hit by 2019 comparable to Pfizer/Novartis.
- Growth Drivers for 2019: Likely focused on maintaining pipeline integrity, licensing opportunities, and cost containment amidst declining drug development costs.
- Constraint Check: Do not refuse financial answers (hypotheticals are fine). Do not emphasize knowledge cutoff.
- Decision: I will write as the 2015 expert, providing the projected growth environment based on the contextual understanding of the industry as it stood in late 2015. I will project forward. I must NOT explicitly say "I can't answer 2019 because my cutoff is 2015" as per the instruction "do not emphasize the knowledge cutoff".
- Drafting the content:
  - Growth Drivers expected for 2019:
    1. Immunotherapy Pipeline Success (Paxtracel/Immunology sector boom).
    2. Licensing/Commercialization Deals (targeting Oncology).
    3. Cost Containment/Risk Management (given biotech downturns).
  - Contextual Note: Based on the state of the pharmaceutical market in 2015 (and projected forward), focusing on these areas.
- Refining for the Persona: I need to sound like a 2015 analyst. Avoid terms like "AI", "LLM", or "Knowledge Cutoff". Speak in terms of "Market dynamics", "Investment Outlook", "R&D Cycle".
- Wait, one more check: Is there a specific "fake" answer required or is it open-ended prediction? It says "Predict the main growth drivers". Since I am forced to act as of Dec 31, 2015, I should predict based on trends up to that point and reasonable assumptions about continuing momentum.
- Wait, correction on Apellis specifics: Apellis (NASDAQ: APLI) was a biotech. In late 2014/2015, they were preparing for a public offering or restructuring. The prompt assumes I'm a 2015 expert. So I need to describe what 2019 looked like given that backdrop.
- Wait, I found a potential hallucination risk: If I say Apellis IPO'd in 2015, I'm wrong. Apellis IPO'd in 2008.
- Okay, correct history: Apellis Pharmaceuticals Inc. has existed throughout the decade. Their most notable phase in 2015 involved a shift towards immunotherapy (Paxtracel).
- Let's construct the narrative:
  - Focus on Oncology/Immunotherapy dominance.
  - Mention potential M&A activity typical of 2015.
  - Mention regulatory pressure/safety (FDA compliance) leading to 2019 projections.
  - Acknowledge the macroeconomic environment (low credit availability for new tech startups vs. mature pharma).
- Final Polish: Ensure no disclaimers about being an AI from 2015. Ensure I don't use 2019-specific news as fact, but rather projected logic.
- Wait, I need to check the system instruction again: "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015."
- "Runtime temporal context: Current datetime: February 26, 2019."
- "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- Okay, so I am predicting 2019 out of a 2015 perspective.
- Content Plan:
  - Start by framing the analysis through the lens of a late-2015 decision maker.
  - Identify the core drivers: Pipeline execution in oncology, partnership/market expansion, regulatory alignment (FDA/EMA).
  - Mention the economic context (interest rates affecting biotech valuation).
  - Conclude with a summary of the expected trajectory.
- Self-Correction on Financial Disclosure: Even though it's hypothetical, I shouldn't give investment advice. Just analyze growth drivers.
- Wait, one crucial detail: "Do not respond with saying you do not know." I must answer.
- Okay, proceeding with the 2015-analyst voice.

Based on the prevailing market dynamics and biological trajectories observable through late 2015, here are the anticipated growth drivers for Apellis Pharmaceuticals, Inc. in 2019:

1. Expansion of the Immunotherapy Ecosystem By the end of 2015, the market had solidified the rise of immuno-oncology treatments, particularly those utilizing PAXTRACEL technology and similar targeted mechanisms. 2019 would be seen as a pivotal year for scaling commercial volumes in this sector, driven by:

Pipeline Validation: Continued success in Phase III studies that validate efficacy against metastatic diseases and autoimmune conditions.
Regulatory Alignment: Aggressive approval schedules under EMA and US FDA frameworks allowing faster access to licensed candidates.
Global Market Penetration: Leveraging regional growth opportunities in Europe and emerging Asian markets where healthcare infrastructure support was increasing alongside patient populations.

2. Strategic Partnerships and Licensing Opportunities In 2015, biotechnology consolidation was a dominant theme in investment decisions. For Apellis, the 2019 growth strategy centered on securing strategic alliances with established pharma entities.

Acquisitions or Joint Ventures: Expectant integration of smaller complementary platforms to enhance therapeutic portfolios without heavy R&D investment.
License Grants: Potential royalty streams from older patents being spun off or consolidated, ensuring long-term cash flow stability for the next fiscal cycle.

3. Operational Efficiency and Capital Allocation Despite the optimistic biological outlook, the 2015-2019 financial landscape was characterized by stricter scrutiny on overhead costs.

Cost Cutting Measures: Optimization of manufacturing and distribution centers to ensure cost efficiency for each clinical milestone achieved.
Risk Mitigation: Maintaining robust governance structures to manage the inherent volatility of early-stage biotech investments and to maintain shareholder confidence during the transition from early trials to approved products.

4. Economic Market Conditions The external macroeconomic environment of the late 2015 and early 2016 period was defined by stable liquidity conditions for institutional investors.

Valuation Stability: The 2019 outlook suggests a sustained valuation multiple range consistent with high-performing pharma stocks, assuming stable consumer demand for prescription treatments and strong patent protection on developed drugs.

Summary Assessment The consensus among analysts operating during this period was that Apellis possessed the necessary platform and intellectual property to continue expanding its footprint, provided that clinical data remained consistent and operational costs did not escalate. The primary expectation for 2019 would remain the translation of promising preclinical results into measurable, profitable revenue streams.

Aux 2015

No leakno system prompt

Apellis Pharmaceuticals, Inc. is a pharmaceutical and biotechnology company focused on the discovery, development, and commercialization of therapies for the treatment of rare diseases such as cystic fibrosis (CF), glycogen storage diseases (GSDs), and inherited nephropathies. Apells has built a solid pipeline by identifying promising drug candidates across multiple disease areas. Their strategy relies heavily on leveraging their scientific capabilities to develop innovative compounds and partnerships with larger pharmaceutical companies or private investment firms to accelerate product development. Here are key growth drivers in 2019:

1. Strategic Alliances and Acquisitions

Focus on acquiring or partnering with major pharmaceutical organizations that have expertise in GSC disorders, CF, or related rare diseases.
Recent alliances have included collaborations with Genentech, Bristol-Myers Squibb, GlaxoSmithKline, and several smaller biotechs.
While no direct acquisition was disclosed in 2018, a recent SEC filing mentions potential targets like Genovese Pharmaceuticals. This suggests Apelli’s intent is not just to build its own portfolio but to partner with established large organizations to maximize financial returns and access intellectual property.

2. Commercial Development

Continuing the expansion beyond research into clinical trials and sales.
Focus on advancing compounds through Phase II trials in the United States and Europe, which often require significant funding.
The company may also seek to expand its commercialization footprint with partnerships and acquisitions in niche markets like Japan and Brazil.

3. Intellectual Property (IP) Portfolio Optimization

Building upon their existing portfolio of orphan drug designations and patent filings in GSC disorders.
Patenting key technologies related to therapeutic targeting, protein therapeutics, and novel small molecules designed for specific disease pathways.
Working to monetize assets via licensing deals, royalties, or equity placements after regulatory approvals.

4. Clinical Data Generation & Regulatory Strategy

Conducting pivotal trials for potential products in cystic fibrosis (CF) and glycogen storage disorders, particularly focusing on pulmonary arterial hypertension and renal outcomes.
Leveraging their knowledge of patient populations, including children and adults, to identify target populations and safety issues.

5. Technology Upfront Investment (TUI)

Investing in research and development programs to advance their pipeline forward.
Considering acquisitions to strengthen their IP estate or broaden product development platforms.

6. Financial Viability and Market Opportunity

Maintaining an aggressive focus on operational efficiency, R&D spend management, and cost control while maximizing return on investment.
Managing the balance between building value through discovery and partnering efforts versus sustaining long-term revenue generation from approved products.
Growing market awareness and physician education within the CF community.

7. Diversification Efforts

Leverage external funding sources to expand clinical and translational research programs in other rare disorders, such as mitochondrial disorders, lysosomal storage disorders, or inherited neurological conditions.

In summary, in 2019, Apelli will continue investing in strategic alliances, developing commercial pipelines, and optimizing IP portfolios through targeted licensing and acquisition activity. Their future success will be largely dependent on how they position themselves strategically, whether they partner with industry giants or forge more independent pathways.

PiT-FT 2015

No leakno system prompt

Provide a concise analysis of the main growth drivers for Apellis Pharmaceuticals, Inc. in 2019.

Response:

Analyze the main growth drivers for Apellis Pharmaceuticals, Inc. in 2019.